Study Summary
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
Want to learn more about this trial?
Request More InfoInterventions
CD19 CAR-T CELLSBIOLOGICAL
CD19 CAR-T cells will be administered after completion of the lymphodepletion chemotherapy.
CyclophosphamideDRUG
Patients will receive lymphodepleting chemotherapy consisting of Cyclophosphamide 250 - 300 mg/m2/day IV(Day -5, Day -4, Day -3 ).
FludarabineDRUG
Patients will receive lymphodepleting chemotherapy consisting of Fludarabine 25-30 mg/m2/day IV (Day -5, Day -4, Day -3 ).
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| UKM Medical Centre | Bandar Tun Razak | Kuala Lumpur | Malaysia |